Boston Scientific to participate in Stifel's 2026 Healthcare Conference
Boston Scientific to participate in Stifel's 2026 Healthcare Conference
PR Newswire
MARLBOROUGH, Mass., Oct. 26, 2026
MARLBOROUGH, Mass., Oct. 26, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2026 Healthcare Conference on Wednesday, November 11, 2026. Kenneth Stein, M.D., senior vice president and global chief medical officer, and Lance Bates, executive vice president and president, Interventional Cardiology & Vascular Therapies, will participate in a 30-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET.
A live webcast and replay of the session will be accessible at https://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com
Lauren Tengler
Investor Relations
+1 (508) 683-4479
BSXInvestorRelations@bsci.com
SOURCE Boston Scientific Corporation
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Buy Trading at Big Discounts
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
United States